If you're considering what to do with your Healthcare Realty Trust shares, or perhaps thinking about making a move, you're not alone. The stock has been making waves, sometimes subtle, sometimes more noticeable. Over just the past week, there was a minimal dip of -0.1%, and the past month has seen a slightly larger decline of -1.8%. Yet, zooming out, things look far sunnier: Healthcare Realty Trust is up 7.7% so far this year and a solid 9.5% over the last twelve months. Of course, anyone who...
If you’ve been tracking SiriusPoint’s stock, you know this isn’t one of those sleepwalking tickers. Whether you’re eyeing that impressive 259.4% gain over the last three years or sizing up this year’s 15.8% return, SiriusPoint has certainly kept things interesting for shareholders. Even with a slight dip over the last month, it’s clear that investors are reassessing the company’s growth prospects and its risk, potentially setting up for the next big move.
Much of the recent momentum seems...
If you have been watching Wolfspeed stock recently, you have likely noticed some eye-catching movement. After a period of relative calm, shares have surged by 18.4% in the last week alone. For anyone weighing an investment decision, that kind of action can signal renewed optimism in the company or a shift in how the market is assessing risk and reward in this situation.
So what is driving all this buzz? Part of it may be broader developments in the semiconductor industry, where Wolfspeed is a...
If you have been eyeing Floor & Decor Holdings or wondering whether it is time to make a move, you are not alone. The stock is down 4.7% in the last week and a steep 18.0% over the past month, reflecting a tough period for specialty retailers as broader macro concerns and sector jitters have weighed on investor confidence. Year-to-date, shares have slipped by 26.5%, and over the past year, the decline is even sharper at 36.0%. Looking at a five-year view, the stock is actually in negative...
Skye Bioscience (SKYE) has scheduled a special call to present topline data from its Phase 2a clinical trial of Nimacimab, focusing on both monotherapy and combination treatment. Updates like these frequently shape investor sentiment around development-stage biotech stocks.
See our latest analysis for Skye Bioscience.
Skye Bioscience’s latest topline clinical update arrives after a period of muted share price action. Its stock closed at $1.90 and has shown minimal momentum over recent months...
If you are looking for the next move on Soho House & Co stock, you have probably noticed its eye-catching trajectory. This is not a slow and steady story, but one with dramatic swings and the kind of big numbers that spark conversation. Just over the past year, Soho House & Co’s shares have surged 69.1%. If you stretch that lens out to three years, we are talking 114.5% growth, which is well beyond what most lifestyle or hospitality names can boast. Even in recent months, the stock has kept...
If you have been watching Rush Enterprises, you may be asking yourself whether now is the moment to buy, hold, or move on. The stock price has slipped by 7.3% in the past week and it is down more than 14% over the last month. Year to date, shares have shed 8.8%. On a longer horizon, however, Rush Enterprises has quietly put together an impressive run, climbing 70.8% over three years and more than doubling investors’ money over five years with a 114.6% gain. That kind of return turns heads,...
The Morning Bull - US Market Morning Update Tuesday, Oct, 7 2025
US stock futures are moving lower ahead of the open as persistent political uncertainty in both the US and Europe weighs on sentiment. With the US government shutdown showing no signs of resolution and French bond yields near multi-year highs because of fiscal and leadership gridlock, investors are focused on how these tensions could drive volatility and put pressure on areas of the market most sensitive to economic momentum and...
If you have been keeping an eye on THOR Industries after its most recent close at $106.41, you are not alone. Investors are asking themselves whether now is the time to get in, hang on, or cash out. Over the past year, the stock has logged a modest 1.6% gain, while its three-year rise of nearly 50% suggests some significant long-term growth. At the same time, the past month has seen the shares slide 5.3%, giving some people pause after a strong start to the year with a 12.6% return...
In the past 60 days, Montrose Environmental Group’s consensus estimate for current year earnings has doubled and the company now holds a top analyst rating from Zacks (Rank #1).
This marked upward revision reflects growing analyst optimism and highlights a significant shift in expectations for Montrose’s near-term financial performance.
We’ll explore how the substantial increase in earnings estimates could influence Montrose Environmental Group’s overall investment narrative and...
RBC Capital has reiterated its positive outlook for Brookfield Renewable, highlighting enhanced growth visibility and strong confidence in the company's long-term expansion plans following recent operational results.
Despite reporting lower-than-expected Q2 2025 profits, Brookfield Renewable saw a 10% year-over-year rise in Funds From Operations, driven largely by its hydropower and distributed energy businesses.
We'll examine how analyst confidence in Brookfield Renewable's operational...
If you’re debating what to do with shares of Arcellx, you’re definitely not alone. It’s the kind of stock that makes investors pause and reconsider, especially after such a striking run. Let’s look at the numbers: Arcellx’s price gained 16.2% over the last month, climbed 6.7% in just seven days, and has rocketed an eye-watering 346.5% over three years. It’s not every day you see those kinds of returns, and the buzz in biotech circles hasn’t hurt either, as recent market developments have...
If you’re holding shares of RBC Bearings, or thinking about jumping in, chances are you’re watching those price swings and wondering: is there more gas in the tank, or is it time to tap the brakes? Even with a minor dip of -2.6% in the past week and -3.4% over the past month, the stock is still up an impressive 25.7% year-to-date. Zoom out to a wider lens, and that momentum looks even stronger with returns of 30.6% over a year, 72.8% over three years, and a whopping 193.1% over five years,...
If you are considering what to do with Essex Property Trust stock right now, you are not alone. Many investors are weighing whether the recent dip is a sign of opportunity or cause for caution. After a three-year return of 32.5% and a five-year gain of 43.5%, Essex has clearly delivered for long-term investors. Lately, though, the story has been a little bumpier. The stock closed recently at $261.34, down 1.8% in the last week, 2.5% for the past month, and 6.5% year to date. Even over the...
On October 6, 2025, Senseonics Holdings announced preliminary unaudited revenue for the third quarter ended September 30, reporting approximately US$8.1 million, an increase of 91% over the same period in 2024, primarily attributed to roughly 160% new patient growth in the U.S.
This upturn in both revenue and new patient adoption highlights more robust market traction, suggesting a potential acceleration in demand for the company’s continuous glucose monitoring systems.
We’ll now explore how...
If you're standing at the crossroads of what to do with your Knife River shares or thinking of putting some capital to work, you're not alone. Knife River’s recent performance has grabbed the attention of both cautious investors and opportunists, sparking plenty of debate on whether the current price fairly reflects the company’s long-term prospects.
Knife River's stock price has seen a difficult stretch lately. Down 3.9% in the last week, 11.6% in the last month, and a hefty 29.2%...
AC Immune (NasdaqGM:ACIU) just shared peer-reviewed data from its Phase 1b/2a trial of ACI-35.030, an active immunotherapy targeting Tau in early Alzheimer's, developed with Janssen. The findings highlight a rapid and sustained antibody response as well as a clean safety profile.
See our latest analysis for AC Immune.
With this encouraging clinical update, AC Immune is starting to turn heads, especially as the company’s latest innovation underscores its growing potential in Alzheimer’s...
In September 2025, Bayer’s Consumer Health division announced it had selected Interpublic Group as its exclusive global creative, production, and media agency partner for iconic self-care brands including Aspirin and Claritin.
This partnership signals Bayer’s commitment to integrated marketing powered by GenAI for both global consistency and tailored local consumer engagement.
We'll review how IPG’s appointment as Bayer’s lead global partner could strengthen its client portfolio and...
